Back

Haymarket Medical Education

  • Antidepressive Agents
  • Narcolepsy
  • Polypharmacy
  • Wakefulness

Wakefulness, Interrupted: Narcolepsy Type 1 and the Evidence for Orexin Agonism – Podcast #3 – Chasing Wakefulness

Jules navigates the complexities of managing his narcolepsy type 1, facing the cumulative burdens of polypharmacy and the reality of treatments that raise safety concerns and offer only partial relief. Within this concluding episode, sleep disorders experts Dr Nancy Foldvary-Schaefer and Dr Thomas E. Scammell analyze the limitations of current symptomatic therapies including alerting agents, oxybates, and antidepressants while looking toward a future where treatment addresses the root cause of the disease: orexin deficiency.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 0.25 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • Podcast / audio
  • Credit · Up to 0.25 credits
  • Commercial Support
  • Released
    Jun 12, 2026
  • Last day to claim credit
    Jun 13, 2027 8 months left